SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Dova Pharmaceuticals, Inc. – DOVA

BALA CYNWYD, October 8, 2019 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Dova Pharmaceuticals, Inc. (“Dova” or “the Company”) (Nasdaq – DOVA -News) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Swedish Orphan Biovitrum AB (“Sobi”).

Under the terms of the transaction, Dova shareholders will receive only an upfront payment of $27.50, along with one non-tradeable CVR of $1.50 per share, for each share of Dova common stock owned. The investigation concerns whether the Dova Board breached its fiduciary duties to shareholders and whether Sobi is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Dova shareholders. For example, an analyst following Dova set a target price of $30.00.

If you own shares of Dova stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA  19004, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.